Kiran Mahajan👩🏾‍🔬

Assistant Professor of Surgery at Washington University in St. Louis |Basic Translation and Clinical Researcher | Official Twitter Page | 🦠🧬🧪🧫⚗️

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

Amino Terminal Acetylation of HOXB13 Regulates the DNA Damage Response in Prostate Cancer
Cancers 2024, 16(9), 1622; https://t.co/3i141jEoe5

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

How do CRPCs escape AR blockade: Unraveling new epigenetic regulators of progression.
https://t.co/3W5dQ3lDrT.

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

Immune-tumor dynamics in prostate cancer :https://t.co/3W5dQ3lDrT.

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

https://t.co/781Tq1FgYR

[Nupam Mahajan👨🏻‍🔬 @NupamMahajan]

https://t.co/RPkNpuWCva

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression.
📷
Trends in Cancer

[Nimrod Barashi, M.D. @Uro_BarashiMD]

Are there molecular features that predispose some men with BPH to develop prostate cancer?

Just published in @Cancers_MDPI

Thanks to all the co-authors for the hard work, but especially to Eric Kim (@WashU_Uro) and @KMahajanLab

https://t.co/jsGCpe86M6

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer https://t.co/cCjnQLh0be

[Nupam Mahajan👨🏻‍🔬 @NupamMahajan]

Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer | Nature Communications https://t.co/ZB4dJ2zmwi

[Nupam Mahajan👨🏻‍🔬 @NupamMahajan]

Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor | Oncogene https://t.co/sLOTgMl2Uo

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

@NupamMahajan @WUSTLmed @WashUSurgery @WashU_Uro @PCFnews @NIHFunding @theNCI Superb paper demonstrating a novel mechanism of action of CRPCs!

[Nupam Mahajan👨🏻‍🔬 @NupamMahajan]

Recent study reveals how treatment-resistant prostate cancer provides its own hormonal fuel.
@WUSTLmed
@WashUSurgery
@WashU_Uro
@PCFnews
@NIHFunding
@theNCI
https://t.co/9gVJLQE4N3

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

Drug triggers immune cells to attack prostate cancer – Washington University School of Medicine in St. Louis https://t.co/Cu6REzsYvD

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

Please check our labs newest publication on the ACK1 kinase in complex with its inhibitor R-9b https://t.co/uMNsmRrfMC

[Prostate Cell News @ProstateCell]

🚨 Fresh from the press!

Dr. @NupamMahajan led a research that showed immune checkpoint blockade treatment of castration-resistant #ProstateCancer patients resulted in the re-activation of ACK1/pY18-CSK signaling.

@WUSTL | @NatureComms

📖 Full story: https://t.co/51K7JNcdKr

[WashU Medicine Department of Surgery @WashUSurgery]

@WashU_Uro Kiran Mahajan senior author @SciReports @NupamMahajan @uropro

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer https://t.co/ZUIxVL0kZJ

[Nupam Mahajan👨🏻‍🔬 @NupamMahajan]

Check out our published paper: Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer @KMahajanLab https://t.co/LL7P5xueuj

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

Check out our published paper: Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer https://t.co/MFBtvhEb1Y

[WashU Medicine Division of Urology @WashU_Uro]

From kidney stones to prostate cancer and everything in between, #WashUUrology faculty members are tackling clinical, basic and translational research projects to discover leading-edge treatments and procedures for a wide range of urological conditions.

[Kiran Mahajan👩🏾‍🔬 @KMahajanLab]

Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting https://t.co/9G7HJEN8bl